Compound: AOD-9604 (hGH 177191 fragment, Tyr-modified)
Originally developed by Metabolic Pharmaceuticals in Australia during the 1990s, this synthetic peptide was designed to harness growth hormones fat-mobilizing properties while avoiding the metabolic complications associated with full-length GH therapy
Alternative Names: Tesamorelin (GHRH Analog), CJC-1295 (Modified GRF 1-29), Ipamorelin (Synthetic Pentapeptide) Tesamorelin & CJC-1295 (Mod GRF 1-29) & Ipamorelin Studies and Research Data Potential Pituitary Signaling Pathways Research on Tesamorelin and CJC-1295 suggests that they may bind to GHRH receptors, potentially initiating intracellular signaling cascades involving cyclic adenosine monophosphate (cAMP) and protein kinase pathways
By keeping peptide production closer to home, we can better control product standards, reduce reliance on uncertain imported inventory, and provide Canadian researchers with a more transparent and reliable source for research peptides
"Vitamin B 12 / Pathophysiology Text"